Mikael Eriksson

List of Publications by Year in Descending Order

159 papers	5,308 citations	36 h-index	70 g-index
166 ext. papers	7,352 ext. citations	7.7 avg, IF	4.77 L-index

#	Paper	IF	Citations
159	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
158	Fibrinogen-like protein 2 in gastrointestinal stromal tumour.. *Journal of Cellular and Molecular Medicine*, **2022**,	5.6	1
157	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. *JAMA Oncology*, **2022**,	13.4	4
156	Interval breast cancer is associated with interferon immune response.. *European Journal of Cancer*, **2022**, 162, 194-205	7.5	1
155	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. *Journal of Clinical Oncology*, **2022**, JCO2101829	2.2	1
154	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.. *Scientific Reports*, **2022**, 12, 6199	4.9	
153	Risk Assessment in Population-Based Breast Cancer Screening.. *Journal of Clinical Oncology*, **2022**, JCO2102827	2.2	1
152	A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care.. *Science Translational Medicine*, **2022**, 14, eabn3971	17.5	1
151	Breast cancer risks associated with missense variants in breast cancer susceptibility genes.. *Genome Medicine*, **2022**, 14, 51	14.4	0
150	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *International Journal of Epidemiology*, **2021**,	7.8	6
149	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. *Cancer*, **2021**, 127, 2934-2942	6.4	11
148	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. *JAMA Network Open*, **2021**, 4, e2114716	10.4	7
147	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. *Journal of Clinical Oncology*, **2021**, 39, 1899-1908	2.2	10
146	Mammographic microcalcifications and risk of breast cancer. *British Journal of Cancer*, **2021**, 125, 759-765	8.7	3
145	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. *European Journal of Cancer*, **2021**, 151, 150-158	7.5	5
144	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *Journal of the National Cancer Institute*, **2021**, 113, 329-337	9.7	14
143	Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses. *International Journal of Cancer*, **2021**, 148, 1338-1350	7.5	4

142	Predictors of mammographic microcalcifications. *International Journal of Cancer*, **2021**, 148, 1132-1143	7.5	3
141	Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population-based cohort study. *International Journal of Cancer*, **2021**, 148, 1351-1359	7.5	3
140	Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns. *International Journal of Cancer*, **2021**, 148, 884-894	7.5	2
139	Opioid Use After Intensive Care: A Nationwide Cohort Study. *Critical Care Medicine*, **2021**, 49, 462-471	1.4	4
138	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
137	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
136	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86	8.3	1
135	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
134	Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*, **2021**, 596, 393-397	50.4	28
133	Postinjury Sepsis-Associations With Risk Factors, Impact on Clinical Course, and Mortality: A Retrospective Observational Study **2021**, 3, e0495		1
132	Mammographic features are associated with cardiometabolic disease risk and mortality. *European Heart Journal*, **2021**, 42, 3361-3370	9.5	1
131	Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. *Breast Cancer Research and Treatment*, **2021**, 190, 451-462	4.4	0
130	Reply to T. Suemasu et al. *Journal of Clinical Oncology*, **2021**, 39, 2966-2968	2.2	
129	Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women. *Cancers*, **2021**, 13,	6.6	3
128	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. *JAMA Oncology*, **2020**, 6, 1241-1246	13.4	40
127	Inclusion of Endogenous Plasma Dehydroepiandrosterone Sulfate and Mammographic Density in Risk Prediction Models for Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 574-581	4	4
126	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
125	The association of single nucleotide polymorphisms (SNPs) with breast density and breast cancer survival: the Malm Diet and Cancer Study. *Acta Radiologica*, **2020**, 61, 1326-1334	2	3

124	Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.. *Journal of Clinical Oncology*, **2020**, 38, 11503-11503	2.2	2
123	Sense of coherence and risk of breast cancer. *ELife*, **2020**, 9,	8.9	1
122	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
121	The impact of alcohol consumption and physical activity on breast cancer: The role of breast cancer risk. *International Journal of Cancer*, **2020**, 147, 931-939	7.5	9
120	CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. *Journal of Clinical Oncology*, **2020**, 38, 548-557	2.2	16
119	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. *Breast Cancer Research*, **2020**, 22, 101	8.3	5
118	Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study. *Clinical Sarcoma Research*, **2020**, 10, 22	2.5	1
117	Rare cancers of unknown etiology: lessons learned from a European multi-center case-control study. *European Journal of Epidemiology*, **2020**, 35, 937-948	12.1	0
116	Hormonal determinants of mammographic density and density change. *Breast Cancer Research*, **2020**, 22, 95	8.3	9
115	Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. *BMC Medicine*, **2020**, 18, 225	11.4	5
114	Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. *Radiology*, **2020**, 297, 327-333	20.5	11
113	Mammographic Density Change and Risk of Breast Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 391-399	9.7	14
112	The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI. *Acta Radiologica*, **2020**, 61, 1600-1607	2	3
111	Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses. *Cancer Research*, **2020**, 80, 1590-1600	10.1	7
110	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
109	Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study. *Breast Cancer Research*, **2019**, 21, 8	8.3	5
108	Determinants of Mammographic Density Change. *JNCI Cancer Spectrum*, **2019**, 3, pkz004	4.6	17
107	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. *Breast Cancer Research*, **2019**, 21, 68	8.3	18

106	Tobacco smoking and alcohol consumption as risk factors for thymoma - A European case-control study. *Cancer Epidemiology*, **2019**, 61, 133-138	2.8	8
105	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
104	Detection of potential microcalcification clusters using multivendor for-presentation digital mammograms for short-term breast cancer risk estimation. *Medical Physics*, **2019**, 46, 1938-1946	4.4	5
103	Comparison of self-reported and register-based hospital medical data on comorbidities in women. *Scientific Reports*, **2019**, 9, 3527	4.9	7
102	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
101	Interval breast cancer is associated with other types of tumors. *Nature Communications*, **2019**, 10, 4648	17.4	14
100	Comparison of the sepsis-2 and sepsis-3 definitions in severely injured trauma patients. *Journal of Critical Care*, **2019**, 54, 125-129	4	3
99	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
98	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. *Journal of Clinical Oncology*, **2019**, 37, 11023-11023	2.2	6
97	Impact of gender on post- traumatic intensive care and outcomes. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, **2019**, 27, 115	3.6	5
96	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. *International Journal of Cancer*, **2019**, 144, 1195-1204	7.5	18
95	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
94	Predicting prolonged sick leave among trauma survivors. *Scientific Reports*, **2019**, 9, 58	4.9	2
93	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2019**, 48, 795-806	7.8	52
92	The BRCA2 c.68-7T□□A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Human Mutation*, **2018**, 39, 729-741	4.7	16
91	A comprehensive tool for measuring mammographic density changes over time. *Breast Cancer Research and Treatment*, **2018**, 169, 371-379	4.4	26
90	Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. *Breast Cancer Research*, **2018**, 20, 14	8.3	5
89	Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening. *Breast Cancer Research*, **2018**, 20, 31	8.3	7

88	Working to improve the management of sarcoma patients across Europe: a policy checklist. *BMC Cancer*, **2018**, 18, 424	4.8	9
87	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. *Tumori*, **2018**, 104, 30-36	1.7	50
86	Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX). *European Journal of Cancer*, **2018**, 99, 78-85	7.5	20
85	Physical activity and mammographic density in an Asian multi-ethnic cohort. *Cancer Causes and Control*, **2018**, 29, 883-894	2.8	2
84	Inherited factors contribute to an inverse association between preeclampsia and breast cancer. *Breast Cancer Research*, **2018**, 20, 6	8.3	9
83	Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. *PLoS ONE*, **2018**, 13, e0193048	3.7	11
82	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
81	Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. *JNCI Cancer Spectrum*, **2018**, 2, pky055	4.6	9
80	Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer. *JNCI Cancer Spectrum*, **2018**, 2, pky071	4.6	10
79	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. *Cancer Research*, **2018**, 78, 6329-6338	10.1	13
78	Thioredoxin a novel biomarker of post-injury sepsis. *Free Radical Biology and Medicine*, **2017**, 104, 138-147	7.8	8
77	The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma. *Monthly Notices of the Royal Astronomical Society: Letters*, **2017**, 88, 341-347	4.3	22
76	Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity. *Cancer Research*, **2017**, 77, 3708-3717	10.1	64
75	Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA). *International Journal of Epidemiology*, **2017**, 46, 1740-1741g	7.8	62
74	Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, 602-609	13.4	92
73	SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour. *British Journal of Cancer*, **2017**, 116, 1195-1202	8.7	12
72	A clinical model for identifying the short-term risk of breast cancer. *Breast Cancer Research*, **2017**, 19, 29	8.3	53
71	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643

70	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
69	Post-trauma morbidity, measured as sick leave, is substantial and influenced by factors unrelated to injury: a retrospective matched observational cohort study. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, **2017**, 25, 100	3.6	5
68	Body size in early life and risk of breast cancer. *Breast Cancer Research*, **2017**, 19, 84	8.3	9
67	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. *Breast Cancer Research*, **2017**, 19, 119	8.3	26
66	Differences in mammographic density between Asian and Caucasian populations: a comparative analysis. *Breast Cancer Research and Treatment*, **2017**, 161, 353-362	4.4	33
65	Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer. *International Journal of Cancer*, **2017**, 140, 34-40	7.5	4
64	Associations between childhood body size and seventeen adverse outcomes: analysis of 65,057 European women. *Scientific Reports*, **2017**, 7, 16917	4.9	4
63	Body mass index and breast cancer survival: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2017**, 46, 1814-1822	7.8	27
62	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
61	Failure rate of standard rescue with leucovorin for high-dose methotrexate (HDMTX) in osteosarcoma.. *Journal of Clinical Oncology*, **2017**, 35, 11028-11028	2.2	
60	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
59	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. *Lancet Oncology, The*, **2016**, 17, 1396-1408	21.7	253
58	Common diseases as determinants of menopausal age. *Human Reproduction*, **2016**, 31, 2856-2864	5.7	20
57	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *Journal of Medical Genetics*, **2016**, 53, 298-309	5.8	83
56	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
55	Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. *Journal of Clinical Oncology*, **2016**, 34, 251-8	2.2	27
54	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. *Journal of Clinical Oncology*, **2016**, 34, 244-50	2.2	131
53	HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. *Oncotarget*, **2016**, 7, 433-45	3.3	11

52	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
51	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
50	Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?. *European Journal of Cancer*, **2016**, 59, 128-133	7.5	33
49	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *American Journal of Human Genetics*, **2016**, 99, 903-911	11	43
48	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. *British Journal of Haematology*, **2016**, 175, 410-418	4.5	118
47	Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross-sectional study. *International Journal of Cancer*, **2016**, 139, 2415-25	7.5	18
46	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis*, **2015**, 36, 256-71	4.6	12
45	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406
44	Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2262-9	2.2	56
43	Identification of novel genetic markers of breast cancer survival. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	38
42	Socio-economic status and co-morbidity as risk factors for trauma. *European Journal of Epidemiology*, **2015**, 30, 151-7	12.1	43
41	Background risk of breast cancer and the association between physical activity and mammographic density. *Breast Cancer Research*, **2015**, 17, 50	8.3	16
40	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	74
39	Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. *Radiotherapy and Oncology*, **2015**, 116, 233-8	5.3	25
38	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
37	Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Research*, **2015**, 17, 58	8.3	24
36	Identification of two novel mammographic density loci at 6Q25.1. *Breast Cancer Research*, **2015**, 17, 75	8.3	18
35	Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia--SSG Central Register 25 years' experience. *Journal of Surgical Oncology*, **2015**, 112, 853-60	2.8	10

34	Acute kidney injury following severe trauma: Risk factors and long-term outcome. *Journal of Trauma and Acute Care Surgery*, **2015**, 79, 407-12	3.3	61
33	The genetic basis of quality of life in healthy Swedish women: a candidate gene approach. *PLoS ONE*, **2015**, 10, e0118292	3.7	6
32	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
31	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84	5.6	36
30	Risk factors and tumor characteristics of interval cancers by mammographic density. *Journal of Clinical Oncology*, **2015**, 33, 1030-7	2.2	82
29	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics*, **2015**, 96, 5-20	11	59
28	Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. *Haematologica*, **2015**, 100, 534-40	6.6	59
27	Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial.. *Journal of Clinical Oncology*, **2015**, 33, 10505-10505	2.2	4
26	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1.. *Journal of Clinical Oncology*, **2015**, 33, 10512-10512	2.2	2
25	In Search for the Genetic Basis of Quality of Life in Healthy Swedish Women--A GWAS Study Using the iCOGS Custom Genotyping Array. *PLoS ONE*, **2015**, 10, e0140563	3.7	1
24	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications*, **2014**, 4, 4999	17.4	87
23	Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. *PLoS ONE*, **2014**, 9, e91031	3.7	17
22	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
21	Area and volumetric density estimation in processed full-field digital mammograms for risk assessment of breast cancer. *PLoS ONE*, **2014**, 9, e110690	3.7	21
20	Automated measurement of volumetric mammographic density: a tool for widespread breast cancer risk assessment. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1764-72	4	52
19	Volumetric mammographic density: heritability and association with breast cancer susceptibility loci. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	15
18	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
17	Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study. *Blood*, **2014**, 124, 1618-1618	2.2	

16	MAP plus maintenance pegylated interferon 2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. *Journal of Clinical Oncology*, **2013**, 31, LBA10504-LBA10504	2.2	14
15	MAP plus maintenance pegylated interferon 2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. *Journal of Clinical Oncology*, **2013**, 31, LBA10504-LBA10504	2.2	2
14	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur. *British Journal of Haematology*, **2012**, 158, 815-816	4.5	1
13	Epidemiological Studies on Cancer and Exposure to Dioxins and Related Compounds **2012**, 303-358		1
12	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.. *Journal of Clinical Oncology*, **2012**, 30, 10081-10081	2.2	2
11	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma.. *Journal of Clinical Oncology*, **2012**, 30, 8074-8074	2.2	
10	Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL A Phase II Trial of the Nordic Lymphoma Group. *Blood*, **2011**, 118, 1602-1602	2.2	
9	Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer: a case-control study in Europe. *Occupational and Environmental Medicine*, **2010**, 67, 837-44	2.1	46
8	R-CHOEP-14 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18 65 Years.. *Blood*, **2010**, 116, 2805-2805	2.2	2
7	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. *Blood*, **2008**, 112, 3604-3604	2.2	
6	Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.. *Blood*, **2007**, 110, LB1-LB1	2.2	
5	European multi-centre case-control study on risk factors for rare cancers of unknown aetiology. *European Journal of Cancer*, **2005**, 41, 601-12	7.5	27
4	Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.. *Blood*, **2005**, 106, 2429-2429	2.2	1
3	Angioid streaks are part of a familial syndrome of dyserythropoietic anaemia (CDA III). *British Journal of Haematology*, **1997**, 98, 845-9	4.5	27
2	Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries		2
1	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2